NASDAQ:VCEL Vericel (VCEL) Stock Forecast, Price & News $34.19 +1.67 (+5.14%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$33.03▼$34.5050-Day Range$31.69▼$39.2552-Week Range$17.30▼$39.90Volume468,222 shsAverage Volume356,377 shsMarket Capitalization$1.63 billionP/E RatioN/ADividend YieldN/APrice Target$41.63 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Vericel MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside21.7% Upside$41.63 Price TargetShort InterestBearish11.76% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.78Based on 11 Articles This WeekInsider TradingSelling Shares$146,840 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.26) to $0.03 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.49 out of 5 starsMedical Sector899th out of 965 stocksBiological Products, Except Diagnostic Industry149th out of 159 stocks 2.4 Analyst's Opinion Consensus RatingVericel has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.63, Vericel has a forecasted upside of 21.7% from its current price of $34.19.Amount of Analyst CoverageVericel has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.76% of the float of Vericel has been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 14, which indicates bearish sentiment.Change versus previous monthShort interest in Vericel has recently decreased by 1.12%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVericel does not currently pay a dividend.Dividend GrowthVericel does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VCEL. Previous Next 3.2 News and Social Media Coverage News SentimentVericel has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Vericel this week, compared to 2 articles on an average week.Search Interest7 people have searched for VCEL on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $146,840.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Vericel is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vericel are expected to grow in the coming year, from ($0.26) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vericel is -117.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vericel is -117.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVericel has a P/B Ratio of 8.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vericel (NASDAQ:VCEL) StockVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.Read More VCEL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCEL Stock News HeadlinesSeptember 22, 2023 | americanbankingnews.comVericel (NASDAQ:VCEL) Shares Gap Up After Analyst UpgradeSeptember 21, 2023 | msn.comTruist Securities Reiterates Vericel (VCEL) Hold RecommendationSeptember 22, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 21, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Vericel (VCEL), Oxford BioMedica (OXBDF)September 20, 2023 | markets.businessinsider.comVericel (VCEL) Gets a Buy from BTIGSeptember 20, 2023 | msn.comVericel's Short Report: Deep Dive Into Knee-Repair Focused Company's 27 Years of LossesSeptember 20, 2023 | finance.yahoo.comVericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in AdultsSeptember 11, 2023 | seekingalpha.comVericel: A Knee-Jerk 'Hold' Worth Its SaltSeptember 22, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 11, 2023 | markets.businessinsider.comBTIG Sticks to Its Buy Rating for Vericel (VCEL)September 6, 2023 | finance.yahoo.comVericel to Present at the Morgan Stanley Global Healthcare ConferenceAugust 10, 2023 | finance.yahoo.comVericel Corp. (VCEL) Rose on Positive Trend in the IndustryAugust 8, 2023 | msn.comBTIG Upgrades Vericel (VCEL)August 3, 2023 | markets.businessinsider.comExpert Ratings for VericelAugust 3, 2023 | msn.comHC Wainwright & Co. Maintains Vericel (VCEL) Buy RecommendationAugust 3, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Vericel (VCEL)August 2, 2023 | finanznachrichten.deVericel Corporation: Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial GuidanceAugust 2, 2023 | finance.yahoo.comVericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial GuidanceAugust 2, 2023 | msn.comVericel beats Q2 top and bottom line estimates; raises FY23 revenue outlookAugust 1, 2023 | markets.businessinsider.comHere's what Wall Street expects from Vericel's earnings reportJuly 20, 2023 | finance.yahoo.comVericel to Report Second-Quarter 2023 Financial Results on August 2, 2023July 17, 2023 | markets.businessinsider.comTruist Financial Sticks to Its Hold Rating for Vericel (VCEL)July 10, 2023 | finance.yahoo.comVericel (NASDAQ:VCEL) shareholders are still up 286% over 5 years despite pulling back 4.5% in the past weekJune 27, 2023 | seekingalpha.comVericel: Multiyear Growth Catalysts, Proprietary Solutions Will Drive Market Cap ExpansionMay 15, 2023 | markets.businessinsider.comBTIG Issues a Hold Rating on Vericel (VCEL)May 11, 2023 | msn.comStephens & Co. Maintains Vericel (VCEL) Overweight RecommendationMay 11, 2023 | msn.comTruist Securities Maintains Vericel (VCEL) Hold RecommendationSee More Headlines Receive VCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter. Email Address VCEL Company Calendar Last Earnings8/02/2023Today9/22/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VCEL CUSIPN/A CIK887359 Webwww.vcel.com Phone(617) 588-5555Fax617-588-5554Employees305Year Founded1989Price Target and Rating Average Stock Price Forecast$41.63 High Stock Price Forecast$44.50 Low Stock Price Forecast$39.00 Forecasted Upside/Downside+21.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,710,000.00 Net Margins-7.39% Pretax Margin-6.99% Return on Equity-6.90% Return on Assets-4.80% Debt Debt-to-Equity RatioN/A Current Ratio5.14 Quick Ratio4.75 Sales & Book Value Annual Sales$163.70 million Price / Sales9.95 Cash FlowN/A Price / Cash FlowN/A Book Value$4.07 per share Price / Book8.40Miscellaneous Outstanding Shares47,640,000Free Float45,165,000Market Cap$1.63 billion OptionableOptionable Beta1.76 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Dominick C. Colangelo Esq. (Age 59)CEO, Pres & Director Comp: $1.42MMr. Joseph Anthony Mara Jr. (Age 47)CFO & Treasurer Comp: $673.44kMr. Michael Halpin (Age 62)Chief Operating Officer Comp: $718.24kMr. Sean C. Flynn (Age 49)Sr. VP, Gen. Counsel & Sec. Comp: $593.24kDr. Jonathan M. Hopper FRCSEd. (Age 61)M.B. Ch.B., Chief Medical Officer Comp: $615.24kMr. Jonathan SiegalPrincipal Accounting Officer, VP & Corp. ControllerMr. Eric BurnsVP of Fin. & Investor RelationsMr. Patrick J. FowlerSr. VP of Corp. Devel. & StrategyMr. Patrick HelfrichVP of Marketing & Commercial StrategyMs. Heidi HassenSr. VP of HRMore ExecutivesKey CompetitorsSpringWorks TherapeuticsNASDAQ:SWTXArcellxNASDAQ:ACLXBioCryst PharmaceuticalsNASDAQ:BCRXRecursion PharmaceuticalsNASDAQ:RXRXIovance BiotherapeuticsNASDAQ:IOVAView All CompetitorsInsiders & InstitutionsBarclays PLCBought 26,760 shares on 9/21/2023Ownership: 0.056%California State Teachers Retirement SystemBought 624 shares on 8/21/2023Ownership: 0.117%Osaic Holdings Inc.Sold 5,141 shares on 8/21/2023Ownership: 0.051%Teachers Retirement System of The State of KentuckyBought 828 shares on 8/21/2023Ownership: 0.031%Legato Capital Management LLCBought 18,560 shares on 8/18/2023Ownership: 0.039%View All Insider TransactionsView All Institutional Transactions VCEL Stock - Frequently Asked Questions Should I buy or sell Vericel stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VCEL shares. View VCEL analyst ratings or view top-rated stocks. What is Vericel's stock price forecast for 2023? 4 equities research analysts have issued 1-year target prices for Vericel's shares. Their VCEL share price forecasts range from $39.00 to $44.50. On average, they expect the company's share price to reach $41.63 in the next twelve months. This suggests a possible upside of 21.7% from the stock's current price. View analysts price targets for VCEL or view top-rated stocks among Wall Street analysts. How have VCEL shares performed in 2023? Vericel's stock was trading at $26.34 at the start of the year. Since then, VCEL stock has increased by 29.8% and is now trading at $34.19. View the best growth stocks for 2023 here. When is Vericel's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our VCEL earnings forecast. How were Vericel's earnings last quarter? Vericel Co. (NASDAQ:VCEL) posted its earnings results on Wednesday, August, 2nd. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.02. The biotechnology company had revenue of $45.92 million for the quarter, compared to analyst estimates of $42.14 million. Vericel had a negative net margin of 7.39% and a negative trailing twelve-month return on equity of 6.90%. The company's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.19) EPS. What ETFs hold Vericel's stock? ETFs with the largest weight of Vericel (NASDAQ:VCEL) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), ALPS Medical Breakthroughs ETF (SBIO) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).Syntax Stratified SmallCap ETF (SSLY). What guidance has Vericel issued on next quarter's earnings? Vericel issued an update on its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $190.00 million-$197.00 million, compared to the consensus revenue estimate of $190.29 million. What is Nick Colangelo's approval rating as Vericel's CEO? 6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Vericel own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA). What is Vericel's stock symbol? Vericel trades on the NASDAQ under the ticker symbol "VCEL." Who are Vericel's major shareholders? Vericel's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.02%), Brown Capital Management LLC (14.53%), State Street Corp (5.22%), Conestoga Capital Advisors LLC (4.91%), Fisher Asset Management LLC (3.55%) and New York State Common Retirement Fund (2.23%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Jonathan Siegal, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman. View institutional ownership trends. How do I buy shares of Vericel? Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vericel's stock price today? One share of VCEL stock can currently be purchased for approximately $34.19. How much money does Vericel make? Vericel (NASDAQ:VCEL) has a market capitalization of $1.63 billion and generates $163.70 million in revenue each year. The biotechnology company earns $-16,710,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. How many employees does Vericel have? The company employs 305 workers across the globe. How can I contact Vericel? Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.vcel.com. The biotechnology company can be reached via phone at (617) 588-5555, via email at ir@vcel.com, or via fax at 617-588-5554. This page (NASDAQ:VCEL) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.